Understanding the within-host dynamics of influenza A virus: From theory to clinical implications

Journal of the Royal Society Interface

Volumn 13, Issue 119, 2016, Pages

  Hadjichrysanthou, Christoforos ^a   Cauët, Emilie ^a   Lawrence, Emma ^a   Vegvari, Carolin ^a   De Wolf, Frank ^a,b   Anderson, Roy M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Janssen Prevention Center   (Netherlands)

Author keywords

Acute viral infection; Immune control; Influenza A; Viral kinetics; Within host modelling

Indexed keywords

ANTIVIRAL AGENTS; CELL DEATH; ESTIMATION; MARKOV PROCESSES; MONTE CARLO METHODS; VIRUSES;

ANALYTIC APPROACH; IMMUNE CONTROL; INFECTION DYNAMICS; INFLUENZA A; INFLUENZA A VIRUS; MARKOV CHAIN MONTE CARLO METHOD; VIRAL INFECTIONS; VIRAL LOAD MEASUREMENTS;

DYNAMICS;

OSELTAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; BASIC REPRODUCTION NUMBER; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE DURATION; HOST; HUMAN; INFECTION RATE; INFLUENZA A (H1N1); INFLUENZA A VIRUS; LIMIT OF QUANTITATION; MARKOV CHAIN; MATHEMATICAL MODEL; MONTE CARLO METHOD; NONHUMAN; TARGET CELL; VIRAL CLEARANCE; VIRAL DECAY RATE; VIRAL PHENOMENA AND FUNCTIONS; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS LOAD; BIOLOGICAL MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA, HUMAN; URINE;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MODELS, IMMUNOLOGICAL; OSELTAMIVIR; VIRAL LOAD;

EID: 84983033941     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2016.0289     Document Type: Article

References (56)

1. Taubenberger J, Morens D. 2008 The pathology of influenza virus infections. Annu. Rev. Pathol. 3, 499-522. (doi:10.1146/annurev.pathmechdis.3.121806.154316)
2. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. 2000 The impact of influenza epidemics on hospitalizations. J. Infect. Dis. 181, 831-837. (doi:10.1086/315320)
3. Thompson WW et al. 2003 Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179-186. (doi:10.1001/jama.289.2.179)
4. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS. 2005 Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437, 209-214. (doi:10.1038/nature04017)
5. Renaud C, Boudreault AA, Kuypers J, Lofy KH, Corey L, Boeckh MJ, Englund JA. 2011 H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg. Infect. Dis. 17, 653-660; quiz 765. (doi:10.3201/eid1704.101429)
6. van der Vries E et al. 2013 Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog. 9, e1003343. (doi:10.1371/journal.ppat.1003343)
7. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. 2006 Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590-7599. (doi:10.1128/jvi.01623-05)
8. Handel A, Longini Jr IM, Antia R. 2007 Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput. Biol. 3, e240. (doi:10.1371/journal.pcbi.0030240)
9. Canini L, Carrat F. 2011 Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J. Virol. 85, 2764-2770. (doi:10.1128/jvi.01318-10)
10. Dobrovolny HM, Baron MJ, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA. 2010 Exploring cell tropism as a possible contributor to influenza infection severity. PLoS ONE 5, e13811. (doi:10.1371/journal.pone.0013811)
11. Handel A, Longini Jr IM, Antia R. 2010 Towards a quantitative understanding of the within-host dynamics of influenza A infections. J. R. Soc. Interface 7, 35-47. (doi:10.1098/rsif.2009.0067)
12. Miao H, Hollenbaugh JA, Zand MS, Holden-Wiltse J, Mosmann TR, Perelson AS, Wu H, Topham DJ. 2010 Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J. Virol. 84, 6687-6698. (doi:10.1128/jvi.00266-10)
13. Saenz RA et al. 2010 Dynamics of influenza virus infection and pathology. J. Virol. 84, 3974-3983. (doi:10.1128/JVI.02078-09)
14. Pawelek KA, Huynh GT, Quinlivan M, Cullinane A, Rong L, Perelson AS. 2012 Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput. Biol. 8, e1002588. (doi:10.1371/journal.pcbi.1002588)
15. Bocharov GA, Romanyukha AA. 1994 Mathematical model of antiviral immune response III. Influenza A virus infection. J. Theor. Biol. 167, 323-360. (doi:10.1006/jtbi.1994.1074)
16. Hancioglu B, Swigon D, Clermont G. 2007 A dynamical model of human immune response to influenza A virus infection. J. Theor. Biol. 246, 70-86. (doi:10.1016/j.jtbi.2006.12.015)
17. Lee HY et al. 2009 Simulation and prediction of the adaptive immune response to influenza A virus infection. J. Virol. 83, 7151-7165. (doi:10.1128/jvi.00098-09)
18. Tridane A, Kuang Y. 2010 Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. Math. Biosci. Eng. 7, 171-185. (doi:10.3934/mbe.2010.7.171)
19. De Clercq E. 2006 Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5, 1015-1025. (doi:10.1038/nrd2175)
20. Gubareva LV, Kaiser L, Hayden FG. 2000 Influenza virus neuraminidase inhibitors. Lancet 355, 827-835. (doi:10.1016/s0140-6736(99)11433-8)
21. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. 2006 Antivirals for influenza in healthy adults: systematic review. Lancet 367, 303-313. (doi:10.1016/S0140-6736(06)67970-1)
22. Hayden FG. 2006 Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res. 71, 372-378. (doi:10.1016/j.antiviral.2006.05.016)
23. Canini L, Conway JM, Perelson AS, Carrat F. 2014 Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study. PLoS Comput. Biol. 10, e1003568. (doi:10.1371/journal.pcbi.1003568)
24. Kamal MA, Gieschke R, Lemenuel-Diot A, Beauchemin CA, Smith PF, Rayner CR. 2015 A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression. Antimicrob. Agents Chemother. 59, 5388-5395. (doi:10.1128/aac.00069-15)
25. Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, Ribeiro RM, Perelson AS. 2008 Modeling amantadine treatment of influenza A virus in vitro. J. Theor. Biol. 254, 439-451. (doi:10.1016/j.jtbi.2008.05.031)
26. Wei X et al. 1995 Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122. (doi:10.1038/373117a0)
27. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. 1996 Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93, 4398-4402. (doi:10.1073/pnas.93.9.4398)
28. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996 HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586. (doi:10.1126/science.271.5255.1582)
29. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995 Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126. (doi:10.1038/373123a0)
30. Nowak M, May RM. 2000 Virus dynamics: mathematical principles of immunology and virology. Oxford, UK: Oxford University Press.
31. Perelson AS. 2002 Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2, 28-36. (doi:10.1038/nri700)
32. Smith AM, Perelson AS. 2011 Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 429-445. (doi:10.1002/wsbm.129)
33. Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CA. 2013 Assessing mathematical models of influenza infections using features of the immune response. PLoS ONE 8, e57088. (doi:10.1371/journal.pone.0057088)
34. Beauchemin CAA, Handel A. 2011 A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. BMC Public Health 11, S7. (doi:10.1186/1471-2458-11-S1-S7)
35. Nowak MA, Bonhoeffer S, Shaw GM, May RM. 1997 Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184, 203-217. (doi:10.1006/jtbi.1996.0307)
36. Ikeda H, de Boer RJ, Sato K, Morita S, Misawa N, Koyanagi Y, Aihara K, Iwami S. 2014 Improving the estimation of the death rate of infected cells from time course data during the acute phase of virus infections: application to acute HIV-1 infection in a humanized mouse model. Theor. Biol. Med. Modell. 11, 22. (doi:10.1186/1742-4682-11-22)
37. Luo S, Reed M, Mattingly JC, Koelle K. 2012 The impact of host immune status on the within-host and population dynamics of antigenic immune escape. J. R. Soc. Interface 9, 2603-2613. (doi:10.1098/rsif.2012.0180)
38. Anderson RM, May RM. 1992 Infectious diseases of humans: dynamics and control. Oxford, UK: Oxford University Press.
39. Diekmann O, Heesterbeek H, Britton T. 2013 Mathematical tools for understanding infectious disease dynamics. Princeton, NJ: Princeton University Press.
40. Diekmann O, Heesterbeek JAP. 2000 Mathematical epidemiology of infectious diseases: model building, analysis and interpretation. New York, NY: Wiley.
41. Rawlins EL, Hogan BL. 2008 Ciliated epithelial cell lifespan in the mouse trachea and lung. Am. J. Physiol. 295, L231-L234. (doi:10.1152/ajplung.90209.2008)
42. Boers JE, den Brok JL, Koudstaal J, Arends JW, Thunnissen FB. 1996 Number and proliferation of neuroendocrine cells in normal human airway epithelium. Am. J. Respir. Crit. Care Med. 154, 758-763. (doi:10.1164/ajrccm.154.3.8810616)
43. Smith AM, Adler FR, McAuley JL, Gutenkunst RN, Ribeiro RM, McCullers JA, Perelson AS. 2011 Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput. Biol. 7, e1001081. (doi:10.1371/journal.pcbi.1001081)
44. Stray SJ, Air GM. 2001 Apoptosis by influenza viruses correlates with efficiency of viral mRNA synthesis. Virus Res. 77, 3-17. (doi:10.1016/S0168-1702(01)00260-X)
45. Martin K, Helenius A. 1991 Transport of incoming influenza virus nucleocapsids into the nucleus. J. Virol. 65, 232-244.
46. Hayden FG et al. 1999 Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282, 1240-1246. (doi:10.1001/jama.282.13.1240)
47. Miao H, Xia X, Perelson AS, Wu H. 2011 On identifiability of nonlinear ODE models and application in viral dynamics. SIAM Rev. 53, 3-39. (doi:10.1137/090757009)
48. Wulff NH, Tzatzaris M, Young PJ. 2012 Monte Carlo simulation of the Spearman-Kaerber TCID50. J. Clin. Bioinform. 2, 5. (doi:10.1186/2043-9113-2-5)
49. Ward CL, Dempsey MH, Ring CJ, Kempson RE, Zhang L, Gor D, Snowden BW, Tisdale M. 2004 Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J. Clin. Virol. 29, 179-188. (doi:10.1016/s1386-6532(03)00122-7)
50. Carlin BP, Louis TA. 1996 Bayes and empirical Bayes methods for data analysis. New York, NY: Chapman and Hall.
51. Svensson Å. 2007 A note on generation times in epidemic models. Math. Biosci. 208, 300-311. (doi:10.1016/j.mbs.2006.10.010)
52. Ekiert DC, Wilson IA. 2012 Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2, 134-141. (doi:10.1016/j.coviro.2012.02.005)
53. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ. 2008 Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am. J. Epidemiol. 167, 775-785. (doi:10.1093/aje/kwm375)
54. Smith AM, Adler FR, Perelson AS. 2010 An accurate two-phase approximate solution to an acute viral infection model. J. Math. Biol. 60, 711-726. (doi:10.1007/s00285-009-0281-8)
55. Ip DKM, Lau LLH, Chan K-H, Fang VJ, Leung GM, Peiris MJS, Cowling BJ. 2015 The dynamic relationship between clinical symptomatology and viral shedding in naturally acquired seasonal and pandemic influenza virus infections. Clin. Infect. Dis. 62, 431-437. (doi:10.1093/cid/civ909)
56. Murillo LN, Murillo MS, Perelson AS. 2013 Towards multiscale modeling of influenza infection. J. Theor. Biol. 332, 267-290. (doi:10.1016/j.jtbi.2013.03.024)